Rohini Naineni1, Vishali Ravi2, Dwijendra Kocherlakota Subbaraya3, Jammula Surya Prasanna4, Veerendranath Reddy Panthula4, Rekha Rani Koduganti5. 1. Reader, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India . 2. Senior Lecturer, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India . 3. Professor and Head, Department of Pedodontics, MNR Dental College and Hospital , Sangareddy, Telangana, India . 4. Professor, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India . 5. Professor and Head, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India .
Abstract
INTRODUCTION:Alendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for growth factors and antibiotics. Drug delivery vehicles, like β-TCP, improve the potency of the drugs by specific local site delivery of the drug, optimal release characteristics and easy handling. AIM: The aim of the this study was to evaluate the bone formation potential of 400μg ALN delivered in β-TCP in the treatment of periodontal intra-osseous defects. MATERIALS AND METHODS:Thirty patients with periodontal defects were randomly assigned to 400μg ALN + β-TCP + Saline (test) group and β-TCP + Saline (active-control) group. Clinical parameters like Clinical Attachment Level (CAL) gain, Probing Depth (PD) reduction, post-operative Gingival Recession (GR) were assessed from the baseline, 3 months and 6 months recordings. Radiographic parameters like Linear Bone Growth (LBG), Percentage Bone Fill (%BF), and change in alveolar crest height (ACH) were assessed from baseline and 6 months radiographs. RESULTS:Mean measurements in the ALN test group for CAL gain (3.4 ± 0.74 mm), PD reduction (4.33 ± 0.82 mm), LBG (2.88 ± 0.88 mm), and %BF (51.98 ± 15.84%) were significantly greater with a p-value <0.05 compared to the mean measurements of CAL gain (2.20 ± 0.86 mm), PD reduction (3.20 ± 1.15 mm), LBG (1.70 ± 0.39 mm), and %BF (30.35 ± 6.88%) of the control group. There was mild alveolar crestal apposition (0.32 ± 0.68 mm) in the ALN test group and mild alveolar crestal resorption (-0.24 ± 0.40 mm) in the control group. CONCLUSION:400μg ALN combined with β-TCP bone graft material was effective in improving soft tissue parameters, inhibiting alveolar crestal resorption and enhancing bone formation, compared to β-TCP alone.
RCT Entities:
INTRODUCTION:Alendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for growth factors and antibiotics. Drug delivery vehicles, like β-TCP, improve the potency of the drugs by specific local site delivery of the drug, optimal release characteristics and easy handling. AIM: The aim of the this study was to evaluate the bone formation potential of 400μg ALN delivered in β-TCP in the treatment of periodontal intra-osseous defects. MATERIALS AND METHODS: Thirty patients with periodontal defects were randomly assigned to 400μg ALN + β-TCP + Saline (test) group and β-TCP + Saline (active-control) group. Clinical parameters like Clinical Attachment Level (CAL) gain, Probing Depth (PD) reduction, post-operative Gingival Recession (GR) were assessed from the baseline, 3 months and 6 months recordings. Radiographic parameters like Linear Bone Growth (LBG), Percentage Bone Fill (%BF), and change in alveolar crest height (ACH) were assessed from baseline and 6 months radiographs. RESULTS: Mean measurements in the ALN test group for CAL gain (3.4 ± 0.74 mm), PD reduction (4.33 ± 0.82 mm), LBG (2.88 ± 0.88 mm), and %BF (51.98 ± 15.84%) were significantly greater with a p-value <0.05 compared to the mean measurements of CAL gain (2.20 ± 0.86 mm), PD reduction (3.20 ± 1.15 mm), LBG (1.70 ± 0.39 mm), and %BF (30.35 ± 6.88%) of the control group. There was mild alveolar crestal apposition (0.32 ± 0.68 mm) in the ALN test group and mild alveolar crestal resorption (-0.24 ± 0.40 mm) in the control group. CONCLUSION: 400μg ALN combined with β-TCP bone graft material was effective in improving soft tissue parameters, inhibiting alveolar crestal resorption and enhancing bone formation, compared to β-TCP alone.
Entities:
Keywords:
Alveolar crestal resorption; Bone formation; Drug delivery vehicle
Authors: Mario Henrique A Verzola; Fausto Frizzera; Guilherme J P L de Oliveira; Rosa M R Pereira; Ubirajara P Rodrigues-Filho; Keico Okino Nonaka; Silvana R P Orrico Journal: Clin Oral Implants Res Date: 2014-10-16 Impact factor: 5.977
Authors: Myron Nevins; William V Giannobile; Michael K McGuire; Richard T Kao; James T Mellonig; James E Hinrichs; Bradley S McAllister; Kevin S Murphy; Pamela K McClain; Marc L Nevins; David W Paquette; Thomas J Han; Michael S Reddy; Philip T Lavin; Robert J Genco; Samuel E Lynch Journal: J Periodontol Date: 2005-12 Impact factor: 6.993
Authors: M Weinreb; H Quartuccio; J G Seedor; T B Aufdemorte; M Brunsvold; E Chaves; K S Kornman; G A Rodan Journal: J Periodontal Res Date: 1994-01 Impact factor: 4.419